<DOC>
	<DOCNO>NCT01660906</DOCNO>
	<brief_summary>This study propose evaluate number chronic , Grade 1 2 , non-hematologic Adverse Events ( AEs ) reduce grade resolve 3 month switch therapy imatinib dasatinib .</brief_summary>
	<brief_title>Phase IV , Open-label , Multicenter Study Dasatinib Chronic-Phase Chronic Myeloid Leukemia ( CP-CML ) Patients With Chronic , Low-grade Non-Hematologic Toxicity Imatinib</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Patients CMLCP patient achieve optimal response imatinib treatment Grade 1 2 nonhematologic adverse event persist least 2 month recur least 3 time precede 12 month , despite best supportive care Men woman Chronic Myeloid Leukemia Chronic Phase ( CMLCP ) Ph+ â‰¥ age 18 Daily Eastern CoOperative Group ( ECOG ) performance status = 0 2 Patient willing able give inform consent Life expectancy &gt; 6 month Adequate renal function Adequate hepatic function Patients pregnant breast feed Men whose partner unwilling avoid pregnancy . Previous treatment tyrosinekinase inhibitor ( TKI ) , except imatinib Current grade 3 4 imatinib related adverse event Prior document T315I mutation Prior diagnosis accelerate phase blast crisis CML Previous loss complete hematologic response ( CHR ) major cytogenetic response ( MCyR ) imatinib Concurrent medical condition uncontrolled infection , cardiovascular disease cardiac failure , congenital long QT syndrome , ventricular arrhythmia , prolong QT interval , second third degree heart block , uncontrolled angina , myocardial infarction ( MI ) last 6 month , uncontrolled hypertension , pulmonary arterial hypertension , pleural pericardial effusion , history bleeding disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>